GLP-1 Agonists Show Potent Neuroprotection in Preclinical Stroke and Parkinson's Disease Models
Background
Despite advances, effective neuroprotective strategies for stroke and Parkinson's disease (PD) remain elusive. Current treatments primarily manage symptoms, leaving a significant gap for disease-modifying therapies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes, have demonstrated promising neuroprotective and anti-inflammatory properties in metabolic contexts. This systematic review investigates their potential in these specific neurodegenerative conditions, exploring mechanisms and neurological outcomes.
Study Design
Researchers conducted a systematic review following PRISMA guidelines, searching Cochrane CENTRAL, PubMed, Web of Science, and Scopus. From 1643 identified records, 13 experimental animal studies published between 2013 and 2026 were included. These studies investigated GLP-1RAs in models of stroke (primarily MCAO models) and Parkinson's disease. Data extraction and risk of bias assessment were performed using the SYRCLE tool, focusing on intervention properties, mechanisms, and major neurological outcomes.
Results
The systematic review of 13 preclinical studies revealed significant neuroprotective effects of GLP-1RAs. In stroke models, GLP-1RAs consistently reduced infarct volume; for instance, liraglutide decreased it by 15.4% ± 1.3%, and linagliptin achieved a 40% reduction. Neurological deficit scores also improved significantly (1.1 ± 0.14; P < 0.05), with infarct size reducing from 36.5% to 8.2% (P = 0.001).
In Parkinson's disease models,
GLP-1RAsled to a notable improvement in motor functions (P < 0.001), preserved dopaminergic neurons, and decreased the aggregation ofα-synuclein.
Mechanistically, GLP-1RAs decreased neuroinflammatory markers (TNF-α, IL-1b, IL-6), oxidative stress markers (ROS, 4-HNE), and apoptotic markers (increased Bcl-2, decreased Bax). Treatment durations ranged from 24 hours to 20 weeks, with varying doses across agents.
Key Findings
- GLP-1RAs significantly reduced infarct volume in stroke models (e.g., liraglutide by 15.4% ± 1.3%, linagliptin by 40%).
- Neurological deficit scores improved significantly in stroke models (1.1 ± 0.14;
P < 0.05). - Motor functions improved notably in Parkinson's disease models (
P < 0.001), alongside dopaminergic neuron preservation. - GLP-1RAs decreased neuroinflammatory (
TNF-α,IL-1b,IL-6), oxidative (ROS), and apoptotic (Bax) markers. - Treatment durations varied from 24 hours to 20 weeks, with differing doses among agents.
Why It Matters
The robust neuroprotective effects of GLP-1RAs observed in preclinical models of stroke and Parkinson's disease provide compelling support for their therapeutic potential beyond metabolic disorders. This review strengthens the rationale for advancing GLP-1RAs into human clinical trials for neurodegenerative conditions. While specific human protocols are still distant, the consistent findings across various animal models and the elucidation of multiple neuroprotective mechanisms (anti-inflammatory, anti-oxidative, anti-apoptotic) suggest a broad applicability. The mention of diverse treatment durations and doses across studies highlights the need for optimized dosing strategies in future research, potentially influencing how these peptides are stacked or timed for neurological benefits.
glp-1-agonist
neuroprotection
stroke
parkinsons-disease
systematic-review
preclinical-animal